We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584131

CAS#: 325795-25-3

Description: BB-83698 is a peptide deformylase inhibitor and potent antimicrobial with excellent activity against streptococci and Moraxella catarrhalis strains.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-10-20. Prices are subject to change without notice.

BB-83698 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 584131
Name: BB-83698
CAS#: 325795-25-3
Chemical Formula: C28H42N4O6
Exact Mass: 530.3104
Molecular Weight: 530.666
Elemental Analysis: C, 63.37; H, 7.98; N, 10.56; O, 18.09

Synonym: BB-83698; BB 83698; BB83698

IUPAC/Chemical Name: Cyclopentanepropanamide, N-((1S)-1-((4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)carbonyl)-2,2-dimethylpropyl)-alpha-((formylhydroxyamino)methyl)-, (alphaR)-


InChi Code: InChI=1S/C28H42N4O6/c1-28(2,3)25(29-26(34)22(17-32(36)18-33)14-20-6-4-5-7-20)27(35)31-12-10-30(11-13-31)16-21-8-9-23-24(15-21)38-19-37-23/h8-9,15,18,20,22,25,36H,4-7,10-14,16-17,19H2,1-3H3,(H,29,34)/t22-,25-/m1/s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Sangshetti JN, Khan FA, Shinde DB. Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem. 2015;22(2):214-36. Review. PubMed PMID: 25174923.

2: Guay DR. Drug forecast - the peptide deformylase inhibitors as antibacterial agents. Ther Clin Risk Manag. 2007 Aug;3(4):513-25. PubMed PMID: 18472972; PubMed Central PMCID: PMC2374925.

3: Wang Q, Wang J, Cai Z, Xu W. Prediction of the binding modes between BB-83698 and peptide deformylase from Bacillus stearothermophilus by docking and molecular dynamics simulation. Biophys Chem. 2008 May;134(3):178-84. doi: 10.1016/j.bpc.2008.02.003. Epub 2008 Feb 16. PubMed PMID: 18321635.

4: Khurdayan V, Bozzo J, Sorbera L. Chronicles in drug discovery. Drug News Perspect. 2005 Jun;18(5):332-6. PubMed PMID: 16193105.

5: Chen D, Yuan Z. Therapeutic potential of peptide deformylase inhibitors. Expert Opin Investig Drugs. 2005 Sep;14(9):1107-16. Review. PubMed PMID: 16144495.

6: Jain R, Chen D, White RJ, Patel DV, Yuan Z. Bacterial Peptide deformylase inhibitors: a new class of antibacterial agents. Curr Med Chem. 2005;12(14):1607-21. Review. PubMed PMID: 16022661.

7: Johnson KW, Lofland D, Moser HE. PDF inhibitors: an emerging class of antibacterial drugs. Curr Drug Targets Infect Disord. 2005 Mar;5(1):39-52. Review. PubMed PMID: 15777197.

8: Ramanathan-Girish S, McColm J, Clements JM, Taupin P, Barrowcliffe S, Hevizi J, Safrin S, Moore C, Patou G, Moser H, Gadd A, Hoch U, Jiang V, Lofland D, Johnson KW. Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob Agents Chemother. 2004 Dec;48(12):4835-42. PubMed PMID: 15561864; PubMed Central PMCID: PMC529202.

9: Lofland D, Difuntorum S, Waller A, Clements JM, Weaver MK, Karlowsky JA, Johnson K. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J Antimicrob Chemother. 2004 Apr;53(4):664-8. Epub 2004 Feb 18. PubMed PMID: 14973152.

10: Azoulay-Dupuis E, Mohler J, Bédos JP. Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother. 2004 Jan;48(1):80-5. PubMed PMID: 14693522; PubMed Central PMCID: PMC310171.

11: Waller AS, Clements JM. Novel approaches to antimicrobial therapy: peptide deformylase. Curr Opin Drug Discov Devel. 2002 Sep;5(5):785-92. Review. PubMed PMID: 12630299.

12: Dubreuil L. [Peptide-deformylase inhibitors, a new class of antibiotics]. Presse Med. 2002 Nov 30;31(38):1810-2. French. PubMed PMID: 12497724.

13: Wise R, Andrews JM, Ashby J. In vitro activities of peptide deformylase inhibitors against gram-positive pathogens. Antimicrob Agents Chemother. 2002 Apr;46(4):1117-8. PubMed PMID: 11897602; PubMed Central PMCID: PMC127088.